Zobrazeno 1 - 10
of 75
pro vyhledávání: '"Johannes M. Ludwig"'
Autor:
Jens M. Theysohn, Aydin Demircioglu, Malte Kleditzsch, Johannes M. Ludwig, Manuel Weber, Lale Umutlu, Yan Li, Malte Kircher, Constantin Lapa, Andreas Buck, Michael Koehler, Moritz Wildgruber, Christian M. Lange, Xavier Palard, Etienne Garin, Ken Herrmann, Michael Forsting, Felix Nensa
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-10 (2022)
Abstract In cirrhotic patients with hepatocellular carcinoma (HCC), right-sided radioembolization (RE) with Yttrium-90-loaded microspheres is an established palliative therapy and can be considered a “curative intention” treatment when aiming for
Externí odkaz:
https://doaj.org/article/2bae8d44c17f47d0a5830705af79eda2
Autor:
Cortlandt M. Sellers, Johannes Uhlig, Johannes M. Ludwig, Jeffrey S. Pollak, Tamar H. Taddei, Stacey M. Stein, Joseph K. Lim, Hyun S. Kim
Publikováno v:
Cancer Medicine, Vol 10, Iss 16, Pp 5395-5404 (2021)
Abstract Background Inflammation and the immune system significantly impact the development, progression, and treatment response of hepatocellular carcinoma (HCC). This retrospective study investigated the neutrophil‐to‐lymphocyte ratio (NLR) as
Externí odkaz:
https://doaj.org/article/ebeddeb203ff408e9028b0dd753e1503
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
Abstract Checkpoint inhibitors have demonstrated clinical impact in colorectal cancer with deficient mismatch repair and high microsatellite instability. However, the majority of patients have disease with stable microsatellites that responds poorly
Externí odkaz:
https://doaj.org/article/c3f1eaec71aa4d68a08a5f210792e245
Autor:
Tiago de Castro, Leonie S. Jochheim, Melanie Bathon, Sabrina Welland, Bernhard Scheiner, Kateryna Shmanko, Daniel Roessler, Najib Ben Khaled, Matthias Jeschke, Johannes M. Ludwig, Jens U. Marquardt, Arndt Weinmann, Matthias Pinter, Christian M. Lange, Arndt Vogel, Anna Saborowski
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Objective: Evaluation of the efficacy and safety of atezolizumab/bevacizumab in a real-world HCC cohort, including patients with impaired liver function and prior systemic therapy. Methods: Retrospective analysis of 147 HCC patients treated with atez
Externí odkaz:
https://doaj.org/article/2d0f146b9c1541eab596b184fa583f50
Autor:
Cortlandt M. Sellers, Johannes Uhlig, Johannes M. Ludwig, Tamar Taddei, Stacey M. Stein, Joseph K. Lim, Hyun S. Kim
Publikováno v:
Cancer Medicine, Vol 8, Iss 13, Pp 5948-5958 (2019)
Abstract Background To investigate the impact of insurance status on outcomes in patients with hepatocellular carcinoma (HCC). Methods Patients diagnosed with HCC in the cancer registry from 2005 to 2016 were retrospectively stratified by insurance g
Externí odkaz:
https://doaj.org/article/b44b874d72fa4173830dbf20e2dfefd1
Publikováno v:
Cancer Medicine, Vol 8, Iss 13, Pp 5916-5929 (2019)
Abstract Background To investigate the neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio (PLR), and systemic immune‐inflammation index (SII) as prognostic biomarkers in intrahepatic cholangiocarcinoma (ICC) with a focus on
Externí odkaz:
https://doaj.org/article/f308a2b7bfb84ded9cf892dd1f7379d2
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-13 (2018)
Abstract Background Immunotherapy is at the forefront of modern oncologic care. Various novel therapies have targeted all three layers of tumor biology: tumor, niche, and immune system with a range of promising results. One emerging class in both pri
Externí odkaz:
https://doaj.org/article/beb5bcf9f277480294b0437be21c9d79
Autor:
Lucas C. Adam, Junaid Raja, Johannes M. Ludwig, Adebowale Adeniran, Scott N. Gettinger, Hyun S. Kim
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-5 (2018)
Abstract Novel approaches with checkpoint inhibitors in immunotherapy continue to be essential in the treatment of non-small cell lung cancer (NSCLC). However, the low rate of primary response and the development of acquired resistance during the imm
Externí odkaz:
https://doaj.org/article/f4d48f789b46413493544b8aa0424e12
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-15 (2017)
Abstract The use of immunomodulation to treat malignancies has seen a recent explosion in interest. The therapeutic appeal of these treatments is far reaching, and many new applications continue to evolve. In particular, immune modulating drugs have
Externí odkaz:
https://doaj.org/article/58a6bad9bdb6476da210f36cef7208b6
Publikováno v:
Molecular Oncology, Vol 10, Iss 7, Pp 1133-1145 (2016)
Treatment of unresectable primary cancer and their distant metastases, with the liver representing one of the most frequent location, is still plagued by insufficient treatment success and poor survival rates. The Sigma‐2 receptor is preferentially
Externí odkaz:
https://doaj.org/article/c8eb6f68fbaa49b5a407d683eea93dcb